Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

  |  Issue: April 2012  |  

The research Dr. Thomas presented found that Rheumavax was safe. Investigators did not observe any major adverse events. The results that the researchers observed were in patients with anticitrullinated protein antibody–treated early RA.

“There’s potential for further development of strategies targeting dendritic cells and cit-peptide in specific HLA-DR groups,” Dr. Thomas said. “The tolerance biomarkers suggest improvement in immune hyperregulation.”

ADVERTISEMENT
SCROLL TO CONTINUE

 

Vanessa Caceres is a freelance medical writer in Bradenton, Fla.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    Dr. Shervin Assassi: New Chair of the ACR Committee on Journal Publications

    Shervin Assassi, MD, MS, was the child of two physicians. His mother practiced obstetrics, and his father was a trauma surgeon. It gave him an appreciation for the hard work that goes into medicine and a fascination for joints. He developed an interest in immunology while in medical school. “It was natural for me to…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…